Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 254-996-9
CAS number: 40601-76-1
In general a substance needs to be dissolved before it can be taken up
from the gastro-intestinal tract. The very low water solubility (less
than 100 ppb) and partition coefficient of 15.3 indicate that this
substance will not readily dissolve in the gastro-intestinal fluid. The
relatively high molecular weight (MW = 699.92 g/mole) is also indicative
for limited passage through biological membranes. The presence of an
ionisable group will further impair the absorption as ionised substances
do not easily pass the gastro-intestinal wall. It is therefore unlikely
that Cyanox 1790 will show a high systemic exposure after oral
Based on the available physico-chemical properties of Cyanox 1790, for
risk assessment purposes the oral absorption of Cyanox 1790 is set at
10%. The results of the toxicity studies do not provide reasons to
deviate from this proposed oral absorption factor. Although a LOAEL of
25-84 mg/kg bw/day has been observed in the short-term repeated dose
toxicity study, it should be noted that the effects observed in the
toxicity study are related to the parent compound Cyanox 1790 including
metabolites of Cyanox 1790. As the present assessment is based on the
physico-chemical properties of the parent compound, no conclusion can be
drawn on the biological availability of the substance after
Once absorbed in the gastro-intestinal tract, Cyanox 1790 might be
metabolized. Excretion of Cyanox 1790 and its metabolites will occur via
the bile (high molecular weight) or the urine (low molecular weight).
Based on the high partition coefficient, Cyanox 1790 may accumulate in
In humans, particles with aerodynamic diameters below 100 µm have the
potential to be inhaled. Based on the particle size of Cyanox 1790,
particles <100 µm which have the potential to be inhaled, are present.
For the particles that have the potential to be inhaled, they will be
settled in the nasopharyngeal region (larger particles <100 µm),
thoracic region (particles <50 µm) or alveolar region (particles <15
µm). Part of the deposits in the nasopharyngeal region will be coughed
or sneezed out of the body, or swallowed, while a part will dissolve
into the mucus lining of the respiratory tract epithelium. For risk
assessment purposes the inhalation absorption is set at 100%.
According to the criteria given in the REACH Guidance (e.g. guidance on
information requirements and chemical safety assessment. Chapter R.7c:
Endpoint specific guidance. European Chemical Agency, May 2008), 10%
dermal absorption will be considered in case MW > 500 and log Pow<
-1 or > 4, otherwise 100% dermal absorption should be used. As the
physico-chemical properties of Cyanox 1790 meet the criteria for limited
dermal absorption, for risk assessment purposes dermal absorption is set
Based on the present available data, no additional conclusions can be
drawn on the distribution, metabolism and excretion of Cyanox 1790 after
dermal and inhalation absorption.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again